New technology which could enable patients to receiving dialysis at home and to have their treatment monitored remotely will be trialled across the UK’s Tees Valley.
The same technology may also benefit people with other chronic health conditions, such as diabetes, heart failure and chronic kidney disease, in the future.
The project has won funding through Q Lab UK and a Health Foundation and NHSX collaboration which aims to explore how to build trust and confidence in technology enabled remote monitoring to help develop digital capabilities in the National Health Service.
The partners will explore barriers and enablers to the uptake of such technologies at home, by patients and their care providers.
The technology will be piloted by the renal team at South Tees Hospital NHS Foundation Trust and partners at Teesside University and What Works Centre for Wellbeing. As well as Alio Medical, a medical technology company from San Francisco, California, which aims to enable patients and their caregivers to monitor key treatment measurements at home, without the need for invasive blood tests or hospital visits.
Dr Jonathan Murray, a renal consultants at South Tees Hospitals NHS Foundation Trust, has led similar pilots among patients receiving dialysis within the hospital. He said:
“Our goal has always been to help develop technologies which can enable patients to have their health monitored remotely, including at home.
“This would empower patients and provide autonomy by effectively enabling patients to monitor their health and treatment around their daily activities, rather than vice versa.
“As the Alio Monitoring System is developing, we recognise it is imperative that we understand which factors matter to patients and would influence their use of such technology at home and this project with Q Lab UK will help us to achieve this.”
John S. Young, professor of translational healthcare at the National Horizons Centre at Teesside University, will manage the project.
Professor Young said: “This project has the potential to make a massive difference to patients’ lives.
“Crucially this is an implementation project rather than a trial. Alio Medical hopes to have the technology approved for clinical use in the near future and the current project will help inform subsequent integration of this technology within care pathways.
“The ultimate aim is for this technology to enable patients to track their potassium levels and other important measurements regularly at home. This could save lives by facilitating timely treatment of abnormal blood results; if potassium levels are too high or too low, this can be fatal.
“Equally, being able to assess blood levels remotely will mean that vulnerable patients are not required to attend hospital for blood tests, something which is particularly important as we recover from the coronavirus pandemic.
“At Teesside University’s National Horizons Centre, we work with healthcare providers and the biomanufacturing industry to develop, test and then deliver innovations to the NHS – providing the patient benefit that unites all our efforts.”
The first phase of the project will see staff and patients working together to explore how they can build trust and confidence in the technology, and identify barriers to implementation.
The second phase aims to utilise experience and learning from the first phase to inform and support wider roll out of the technology, once the technology has completed final regulatory approvals.
Dave Karaguntla, CEO of Alio, said: “We are pleased to be collaborating with South Tees and the NHS.
“Their tremendous support and collaboration is providing Alio with the ability to evaluate our dialysis patient monitoring system and how it will provide significant numbers of dialysis patients under their care with greater control over their own health.
“The partnership with Alio and South Tees / NHS will support Alio’s key objective of improving patient outcomes by enabling physicians to deliver the best patient care possible.”
Pingback: Whole blood exchange could offer therapy for Alzheimer’s